MedPath

Insulin in Total Parenteral Nutrition

Phase 4
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Regular insulin added to TPN bag
Drug: Subcutaneous glargine insulin
Registration Number
NCT02706119
Lead Sponsor
Fundación Pública Andaluza Progreso y Salud
Brief Summary

Analyze the level of metabolic control achieved with a routine of regular insulin in the parenteral nutrition (PN) reservoir in addition to subcutaneous glargine insulin, versus only regular insulin in the PN reservoir.

Detailed Description

A pattern of basal insulin (using subcutaneous insulin glargine and regulating the stock as prandial), plus regular subcutaneous insulin as rescue, applied to total parenteral nutrition (TPN) should be as effective (glycemic control, variability) and safe (hypoglycemia) as the usual (regular insulin inside the TPN reservoir and subcutaneous insulin as rescue) in patients with type 2 diabetes critics.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
163
Inclusion Criteria
  • Adults (>18 years)
  • Previously diagnosed with diabetes mellitus.
  • Hospitalized but without intensive cares.
  • Have indication of total parenteral nutritional support (TPN, meaning the covering over 70% of the estimated daily requirements intravenously) for a minimum of 5 days.
  • Signature of informed consent.
Exclusion Criteria
  • Diabetes mellitus type 1, diabetes secondary to total pancreatectomy.
  • Patients with intensive cares.
  • Patients who have been prescribed TPN in intensive cares unity more than 48 hours before admission to hospitalization.
  • Intradialytic parenteral nutrition.
  • Patients under 18 or pregnant women.
  • Patients with renal insufficiency stage 3 B (glomerular filtration rate < 45 mL / min).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Regular insulinRegular insulin added to TPN bagRegular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
Glargine insulinSubcutaneous glargine insulinSingle dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
Glargine insulinRegular insulin added to TPN bagSingle dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
Primary Outcome Measures
NameTimeMethod
Basal blood glucose value before starting TPNBefore starting total parenteral nutrition

Basal glucose value before starting TPN (in mg/dL).

Periodical blood glucoseEvery 6h during 15 days of treatment

All blood glucose values (in mg/dL) every 6 hours during 15 days of TPN infusion.

Variation of average blood glucose compared with total dose of insulinIn days 1, 5 and 15 of treatment

Variation of average glucose (in mg/dL) compared with total dose of insulin (in mL), in days 1, 5 and 15 of treatment.

Number of hypoglycaemiaDuring TPN treatment up to 15 days

Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 70 mg/dL during TPN treatment up to 15 days.

Number of severe hypoglycaemiaDuring TPN treatment up to 15 days

Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 40 mg/dL during TPN treatment up to 15 days.

Hypoglycemia blood glucose valuesThrough study completion, an average of 15 days.

If the patient refers typical symptoms of hypoglycemia, a measure of blood glucose (in mg/mL) is immediately taken to check the level

Hypoglycemia symptomsThrough study completion, an average of 15 days.

If blood glucose \<70 mg / dL, it is recorded whether or not the patient has symptoms consistent with hypoglycemia and how the episode terminates

Secondary Outcome Measures
NameTimeMethod
Standard deviation of blood glucoseAt day 15 of treatment

Standard deviation of blood glucose (SD): Expressed in milligrams per deciliter (in mg/dL).

Blood glucose coefficient of variation (CV)At day 15 of treatment

Coefficient of variation (CV): Expressed as a percentage (%). The ratio of the standard deviation of the blood glucoses values (in mg/dL) and the average blood glucose (in mg/dL), multiplied by 100.

Trial Locations

Locations (32)

Hospital Clínico Universitario Virgen de la Arrixaca

🇪🇸

El Palmar, Murcia, Spain

Hospital Arquitecto Marcide-Naval

🇪🇸

Ferrol, A Coruña, Spain

Hospital de Cabueñes

🇪🇸

Gijón, Asturias, Spain

Hospital de Mérida

🇪🇸

Mérida, Badajoz, Spain

Hospital General Mancha Centro

🇪🇸

Alcázar de San Juan, Ciudad Real, Spain

Complejo Hospitalario de Navarra

🇪🇸

Pamplona, Navarra, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Hospital Universitario Infanta Cristina

🇪🇸

Badajoz, Spain

Hospital Universitario Reina Sofía

🇪🇸

Córdoba, Spain

Hospital Universitario Nuestra Señora de la Candelaria

🇪🇸

Tenerife, Spain

Hospital Universitario Virgen de la Victoria

🇪🇸

Málaga, Spain

Hospital Clínico San Carlos

🇪🇸

Madrid, Spain

Hospital Universitario y Politécnico La Fe

🇪🇸

Valencia, Spain

Hospital Clínico Universitario de Valladolid

🇪🇸

Valladolid, Spain

Hospital Universitario Miguel Servet

🇪🇸

Zaragoza, Spain

Hospital Universitario Severo Ochoa

🇪🇸

Leganés, Madrid, Spain

Complejo Hospitalario Universitario de Albacete

🇪🇸

Albacete, Spain

Hospital Universitario Gregorio Marañón

🇪🇸

Madrid, Spain

Hospital General Universitario de Alicante

🇪🇸

Alicante, Spain

Complejo Asistencial Universitario de León

🇪🇸

León, Spain

Hospital de Sant Joan Despi Moisès Broggi (Consorci Sanitari Integral)

🇪🇸

Barcelona, Spain

Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Universitario Principe de Asturias

🇪🇸

Alcalá de Henares, Madrid, Spain

Hospital Son Llátzer

🇪🇸

Palma de Mallorca, Baleares, Spain

Hospital Universitario de Fuenlabrada

🇪🇸

Fuenlabrada, Madrid, Spain

Hospital Universitario Puerta de Hierro

🇪🇸

Majadahonda, Madrid, Spain

Hospital Universitario Bellvitge

🇪🇸

Barcelona, Spain

Complejo Hospitalario de Jaén

🇪🇸

Jaén, Spain

Hospital Universitario de Guadalajara

🇪🇸

Guadalajara, Spain

Hospital Universitario Virgen del Rocío

🇪🇸

Sevilla, Spain

Hospital Regional Universitario de Málaga

🇪🇸

Málaga, Spain

Hospital Clínico Universitario Lozano Blesa

🇪🇸

Zaragoza, Spain

© Copyright 2025. All Rights Reserved by MedPath